Frontlight ResearchEarly access
CompletedPhase 1
Phase 1 Clinical Trial of CordSTEM-ST
Key facts
- Who runs it
- CHABiotech CO., Ltd
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 6 people enrolled
- Started
- 30 Aug 2024
- Ended
- 28 Apr 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- umbilical cord-derived mesenchymal stem cell
- Record updated
- 19 November 2025
Who can take part
- Age
- 25 years to 39 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Females aged ≥ 25 years and < 40 years
- Individuals diagnosed with premature ovarian insufficiency: Individuals who have a follicle stimulating hormone (FSH) level of 40 IU/L or higher in the results of two tests conducted at least 4 weeks apart and are amenorrheic for at least 4 months
- Individuals who voluntarily decide to participate and provide written consent
Who cannot take part
- Individuals diagnosed with polycystic ovary syndrome
- Individuals with any other conditions that may affect the result of this study
- Individuals diagnosed with primary amenorrhea*; No secondary sex characteristics by age 13, Absence of menarche for 5 years after initial breast development, or Absence of menstruation by age 15
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This clinical study will evaluate the safety and tolerability of CordSTEM-ST after administering a single dose in patients with premature ovarian insufficiency (POI), as well as identify the maximum tolerated dose (MTD) and evaluate the potential therapeutic effects.
The 2 groups in the trial
- Study Group 1 (Low dose CordSTEM-ST)Treatment being tested
Low dose CordSTEM-ST, 1 (single) administration
Treatment: umbilical cord-derived mesenchymal stem cell
- Study Group 2 (High dose CordSTEM-ST)Treatment being tested
High dose CordSTM-ST, 1 (single) administration
Treatment: umbilical cord-derived mesenchymal stem cell
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Single-dose, Phase 1 Clinical Trial to Evaluate the Safety, and Tolerability of Allogeneic Umbilical Cord-derived Mesenchymal Stem Cell Therapy in Patients With Premature Ovarian Insufficiency
- Record updated
- 19 November 2025